###### Editorial Note on [Part 113](/current/title-9/part-113?toc=1)

#### Editorial Note:

Nomenclature changes to part 113 appear at [79 FR 55969](https://www.federalregister.gov/citation/79-FR-55969), Sept. 18, 2014.

#### § 113.212 Bursal Disease Vaccine, Killed Virus.

Bursal Disease Vaccine, Killed Virus, shall be prepared from virus-bearing cell culture fluids or embryonated chicken eggs. Only Master Seed which has been established as pure, safe, and immunogenic shall be used for preparing seeds for vaccine production. All serials shall be prepared from the first through the fifth passage from the Master Seed.

(a) The Master Seed shall meet the applicable requirements prescribed in [§ 113.200](/on/2024-07-03/title-9/section-113.200).

(b) Each lot of Master Seed shall be tested for pathogens by the chicken embryo inoculation test prescribed in [§ 113.37](/on/2024-07-03/title-9/section-113.37), except that, if the test is a No Test because of a vaccine virus override, the chicken inoculation test prescribed in [§ 113.36](/on/2024-07-03/title-9/section-113.36) may be conducted and the virus judged accordingly.

(c) The immunogenicity of vaccine prepared in accordance with the Outline of Production shall be established by a method acceptable to Animal and Plant Health Inspection Service. Vaccine used for this test shall be at the highest passage from the Master Seed and prepared at the minimum preinactivation titer specified in the Outline of Production. The test shall establish that the vaccine, when used as recommended on the label, is capable of inducing an immune response in dams of sufficient magnitude to provide significant protection to offspring.

(d) *Test requirements for release.* Each serial and subserial shall meet the applicable general requirements prescribed in [§ 113.200](/on/2024-07-03/title-9/section-113.200) and the special requirements in this paragraph. Any serial or subserial found unsatisfactory by a prescribed test shall not be released.

(1) *Safety.* Vaccinates used in the potency test in [paragraph (d)(2)](/on/2024-07-03/title-9/section-113.212#p-113.212(d)(2)) of this section shall be observed each day during the prechallenge period. If unfavorable reactions attributable to the vaccine occur, the serial is unsatisfactory. If unfavorable reactions which are not attributable to the vaccine occur, the test is a No Test and may be repeated. If the test is not repeated, the serial is unsatisfactory.

(2) *Potency.* Bulk or final container samples of completed product from each serial shall be tested for potency using the two-stage potency test provided in this paragraph.

(i) *Vaccinates.* Inject each of 21 susceptible chickens 14 to 28 days of age, properly identified and obtained from the same source and hatch, with one dose of vaccine by the route recommended on the label and observe for at least 21 days.

(ii) *Controls.* Retain at least 10 additional chickens from the same source and hatch as unvaccinated controls.

(iii) *Challenge.* Twenty-one to 28 days postvaccination, challenge 20 vaccinates and 10 controls by eyedrop with a virulent infectious bursal disease virus furnished or approved by Animal and Plant Health Inspection Service.

(iv) *Postchallenge period.* Four days postchallenge, necropsy all chickens and examine each for gross lesions of bursal disease. For purposes of this test, gross lesions shall include peribursal edema and/or edema and/or macroscopic hemorrhage in the bursal tissue. Vaccinated chickens showing gross lesions shall be counted as failures. If at least 80 percent of the controls do not have gross lesions of bursal disease in a stage of the test, that stage is considered inconclusive and may be repeated. In a valid test, the results shall be evaluated according to the following table:

| Stage | Number of vaccinates | Cumulative number of vaccinates | Cumulative total number of failures for— | |
| --- | --- | --- | --- | --- |
| Satisfactory serial | Unsatisfactory serial |
| 1 | 20 | 20 | 3 or less | 6 or more. |
| 2 | 20 | 40 | 8 or less | 9 or more. |

(v) If four or five vaccinates show lesions of bursal disease in the first stage, the second stage may be conducted in a manner identical to the first stage. If the second stage is not conducted, the serial is unsatisfactory.

(vi) If the second stage is used, each serial shall be evaluated according to the second part of the table on the basis of cumulative results.

[[50 FR 434](https://www.federalregister.gov/citation/50-FR-434), Jan. 4, 1985. Redesignated at [55 FR 35562](https://www.federalregister.gov/citation/55-FR-35562), Aug. 31, 1990, as amended at [56 FR 66784](https://www.federalregister.gov/citation/56-FR-66784), [66786](https://www.federalregister.gov/citation/56-FR-66786), Dec. 26, 1991; [79 FR 55969](https://www.federalregister.gov/citation/79-FR-55969), Sept. 18, 2014]